Categories: News

9 Meters Biopharma, Inc. to Present at Oppenheimer’s Rare & Orphan Disease Summit

RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company’s CEO, John Temperato will present a corporate update at Oppenheimer’s
Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

Oppenheimer’s Rare & Orphan Disease Summit

Date: May 21, 2021
Time: 3:45 – 4:25 p.m. (ET)
Participation: Management will be available for 1-on-1 meetings
Webcast: https://wsw.com/webcast/oppenheimer12/nmtr/2813759

* a replay will be available following the presentation for 90 days

Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with 9 Meters during the respective conference.

For more information about Oppenheimer’s Rare & Orphan Disease Summit, please refer to the conference website.

About 9 Meters Biopharma
9 Meters Biopharma, Inc. (“the Company”) is a rare and unmet needs-focused gastroenterology company. The Company is advancing vurolenatide, a proprietary long-acting GLP-1 agonist, into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for symptom improvement in non-responsive celiac disease.

For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Corporate Contacts:

Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com

Media Contact:

Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626

Investor Contact:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

SOURCE: 9 Meters Biopharma

View source version on accesswire.com:
https://www.accesswire.com/647477/9-Meters-Biopharma-Inc-to-Present-at-Oppenheimers-Rare-Orphan-Disease-Summit

Staff

Recent Posts

KORU Medical Systems to Participate in Piper Sandler’s 36th Annual Healthcare Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical…

11 hours ago

Metro Inc. Prices Aggregate C$500 Million Senior Unsecured Notes Offering

/NOT FOR DISSEMINATION IN THE UNITED STATES/ MONTRÉAL, Nov. 25, 2024 /CNW/ - METRO INC. ("Metro")…

11 hours ago

LOOPBACK ANALYTICS NAMED ONE OF THE DALLAS BUSINESS JOURNALS’ BEST PLACES TO WORK FOR 2024

DALLAS, Nov. 25, 2024 /PRNewswire/ -- Loopback Analytics has been honored by the Dallas Business Journal as…

11 hours ago

Mercy Drives Conversation on AI Use in Health Care at ‘CHAI on the Hill’

 Mercy the only health care organization represented in policy discussion ST. LOUIS, Nov. 25, 2024…

11 hours ago

Catalight Partners with Nabla to Reduce Practitioner Documentation Burden and Elevate Autism and I/DD Care

After a successful 6-week pilot program, Nabla's ambient AI assistant is rolling out to Catalight's…

11 hours ago